A team at the University of Hong Kong has created a nasal spray that, when used within 30 minutes of an ischemic stroke, reduces brain damage by more than 80% in preclinical studies. The spray works without needles, surgery, or hospital equipment — making it the first tool designed to protect the brain before an ambulance even arrives.
At a glance
- NanoPowder nasal spray: Researchers at HKUMed spent over a decade building the “Nano-in-Micron” technology platform that makes the spray possible, encapsulating neuroprotective agents in particles small enough to travel from the nose directly to the brain.
- Blood-brain barrier: More than 90% of drug candidates targeting the central nervous system fail in clinical trials because they cannot cross this barrier — the nasal spray bypasses it entirely through the nose-to-brain pathway.
- Prehospital stroke treatment: The spray is designed not to replace hospital care but to extend the window for effective treatment, giving patients crucial extra minutes before they reach an emergency room.
Why stroke treatment has been so hard to improve
Ischemic stroke — caused by a blocked blood vessel cutting off oxygen to the brain — is the second leading cause of death and disability worldwide. It costs healthcare systems more than US$890 billion every year.
Current treatments focus on clearing the clot, either with drugs or mechanical thrombectomy. Both work, but only inside a very narrow window of time, and only for patients who reach a fully equipped hospital fast enough. More than 85% of stroke patients never receive timely treatment. Even among those who do, more than half fail to achieve full functional recovery.
The core problem is time. Brain cells die within minutes of losing oxygen. Every intervention so far has required patients to already be inside a hospital before protection begins.
How the nasal spray works
The team, led by Professor Aviva Chow Shing-fung from HKUMed’s Department of Pharmacology and Pharmacy and Dr. Shao Zitong from the InnoHK Advanced Biomedical Instrumentation Centre, engineered a solution that works in four steps: inhalation, deposition, de-agglomeration, and delivery.
When inhaled, micron-sized powder particles travel into the nasal cavity and settle in the target area. On contact with nasal mucus, they break apart into nanoparticles small enough to travel along the nose-to-brain nerve pathway — arriving at the brain without crossing the blood-brain barrier at all.
“The nasal spray is characterised by its quick response, portability, and user-friendliness,” said Professor Chow. “It allows patients to receive early protection en route to hospital or even within the community, significantly slowing the death of brain cells under ischemic conditions and effectively preserving still-viable brain tissues, thereby buying valuable time for subsequent treatments.”
In animal studies, a single dose administered within 30 minutes of stroke onset reduced ischemic infarction — the area of dead brain tissue — by more than 80%. The drug appeared to reduce brain inflammation, prevent cell death, and preserve the integrity of the blood-brain barrier itself.
A shift from treatment to protection
Dr. Shao frames the breakthrough as a philosophical shift as much as a technical one. “After a stroke, every second matters,” he said. “Even an additional ten minutes of brain protection might determine whether a patient can walk or speak in the future.”
That reframe — from treating damage after the fact to protecting the brain while the patient is still in transit — is what makes this approach different. Existing stroke protocols are built around the hospital. This one is built around the patient, wherever they happen to be.
The spray won the Special Grand Prize and Gold Medal with Congratulations of the Jury at the 51st International Exhibition of Inventions Geneva, one of the world’s most prominent platforms for recognizing applied scientific innovation.
What comes next
The research team is now moving into toxicology studies and clinical trials. Their goal is to make the spray available in pharmacies and community settings as a standard emergency first-aid product — the kind of thing a bystander or family member could use while waiting for an ambulance, the way an EpiPen is used for allergic reactions.
The underlying “Nano-in-Micron” platform is not limited to stroke. The same technology can deliver small-molecule drugs, biologics, and traditional Chinese medicine compounds. Researchers believe it could eventually be adapted for Alzheimer’s disease, motor neuron diseases, and infections like meningitis — conditions that share the same fundamental obstacle of getting medication past the blood-brain barrier.
The project received support from Hong Kong’s Innovation and Technology Commission, the Hong Kong–Shenzhen Innovation and Technology Park, and HKUMed’s Technology Transfer Unit. The team is actively gathering feedback from emergency physicians and neurologists to align the product with real-world clinical workflows.
It is worth being honest about where this stands: preclinical results, however striking, do not always survive the transition to human trials. Clinical testing will take years, and regulatory approval in any major market adds more time still. But the underlying science is sound, the need is vast, and the simplicity of the delivery mechanism — a nasal spray anyone can use — gives this one unusual potential to reach patients who have historically been left behind.
Read more
For more on this story, see: HKUMed press release
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on Hong Kong
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
